The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
We talk to Giffin Daughtridge, CEO of medical diagnostics company, UrSure, about treatment adherence and the impact of long-acting cabotegravir as injectable PrEP.
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
An Avert spotlight on the HIV response – we reflect on the most important take-homes from the UNAIDS 2019 Global Report.
With news of another patient ‘cured’ we look back at 5 big moments in cure research and what they really mean
Harm reduction for the 15.6 million people who inject drugs remains a critical cornerstone to respond to the global epidemics of HIV and hepatitis C – but progress has stagnated.
On the 30th anniversary of World AIDS Day, we look back at the difference in the AIDS identity from the 1980s to 2018.
Sustained action is needed now if we are to capitalise on the opportunity to eliminate viral hepatitis by 2030.
Getting on top of the tuberculosis epidemic requires renewed attention, and bringing HIV out of isolation.
Opportunities to increase access to the hepatitis C cure exist – but strong political will is needed and many countries are failing to benefit from cheaper generics.
On International Youth Day (12 August), we look at the importance of youth involvement and safe spaces to respond to the HIV challenge related to the youth bulge.
